ERBB2 and breast carcinoma: In terms of neoadjuvant therapy for HER2‐positive operable breast cancer patients, the phase 3 KRISTINE trial explored T‐DM1 plus pertuzumab (T‐DM1+P, also as adjuvant therapy) versus docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH+P, followed by adjuvant trastuzumab plus pertuzumab), and patients in the T‐DM1+P group had a lower pathologic complete response rate (44.4% vs. 55.7%; p = 0.016) and fewer grade ≥3 AEs (13% vs. 64%).151